1.Klompas M, Khan Y, Kleinman K, Evans RS, Lloyd JF, Stevenson K, et al. Multicenter evaluation of a novel surveillance paradigm for complications of mechanical ventilation. PloS One. 2011; 6(3): e18062
2.Klompas M, Magill S, Robicsek A, Strymish JM, Kleinman K, Evans RS, et al. Objective surveillance definitions for ventilator-associated pneumonia. Critical Care Medicine. 2012; 40(12): 3154-61
3.Pouly O, Lecailtel S, Six S, Préau S, Wallet F, Nseir S, et al. Accuracy of ventilator-associated events for the diagnosis of ventilator-associated lower respiratory tract infections. Annals of Intensive Care. 2020; 10(1): 6
4.Aygün G, Demirkiran O, Utku T, Mete B, Urkmez S, Yilmaz M, et al. Environmental contamination during a carbapenem-resistant acinetobacter baumannii outbreak in an intensive care unit. The Journal of Hospital Infection. 2002; 52(4): 259-62
5.Inchai J, Pothirat C, Bumroongkit C, Limsukon A, Khositsakulchai W, Liwsrisakun C. Prognostic factors associated with mortality of drug-resistant acinetobacter baumannii ventilator-associated pneumonia. Journal of intensive care. 2015; 3: 9
6.Shu H, Li L, Wang Y, Guo Y, Wang C, Yang C, et al. Prediction of the risk of hospital deaths in patients with hospital-acquired pneumonia caused by multidrug-resistant acinetobacter baumannii infection: A multi-center study. Infection and Drug Resistance. 2020; 13: 4147-54
7.Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. The Lancet Infectious Diseases. 2006; 6(9): 589-601
8.Inci A, Toker MK, Bicer IG, Derbent A, Salihoglu Z. Determination of colistin-related nephrotoxicity and risk factors in intensive care unit. Northern Clinics of Istanbul. 2018; 5(2): 120-4
9.Arslan BY, Arslan F, Erkalp K, Alagöl A, Sevdi MS, Yıldız G, et al. Luteolin ameliorates colistin-induced nephrotoxicity in the rat models. Renal Failure. 2016; 38(10): 1735-40
10.Patient Safety Component Manual, Chapter 10: Ventilator-Associated Event (VAE): National Healtcare Safety Network (NHSN); 2020 [cited 2020 January]. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/pcsmanual_current.pdf.
11.Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Critical Care (London, England). 2013; 17(1): 204
12.Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2005; 40(9): 1333-41
13.Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2012; 54(5): 670-80
14.Fang WF, Fang YT, Huang CH, Chen YM, Chang YC, Lin CY, et al. Risk factors and associated outcomes of ventilator-associated events developed in 28 days among sepsis patients admitted to intensive care unit. Scientific Reports. 2020; 10(1): 12702
15.Raoof S, Baumann MH. An official multi-society statement: ventilator-associated events: the new definition. Critical Care Medicine. 2014; 42(1): 228-9
16.Magill SS, Li Q, Gross C, Dudeck M, Allen-Bridson K, Edwards JR. Incidence and characteristics of ventilator-associated events reported to the national healthcare safety network in 2014. Critical Care Medicine. 2016; 44(12): 2154-62
17.Magill SS, Klompas M, Balk R, Burns SM, Deutschman CS, Diekema D, et al. Developing a new, national approach to surveillance for ventilator-associated events. American Journal of Critical Care: An Official Publication, American Association of Critical-Care Nurses. 2013; 22(6): 469-73
18.Klompas M. Ventilator-associated events: What they are and what they are not. Respiratory Care. 2019; 64(8): 953-61
19.Liu J, Zhang S, Chen J, Mao Y, Shao X, Li Y, et al. Risk factors for ventilator-associated events: A prospective cohort study. American Journal of Infection Control. 2019; 47(7): 744-9
20.Wu VKS, Fong C, Walters AM, Lele AV. Prevalence, clinical characteristics, and outcomes related to ventilator-associated events in neurocritically ill patients. Neurocritical Care. 2020; 33(2): 499-507
21.Fan Y, Gao F, Wu Y, Zhang J, Zhu M, Xiong L. Does ventilator-associated event surveillance detect ventilator-associated pneumonia in intensive care units? A systematic review and meta-analysis. Critical Care (London, England). 2016; 20(1): 338
22.Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrobial Agents and Chemotherapy. 2010; 54(10): 4503-5
23.Ghlissi Z, Hakim A, Mnif H, Ayadi FM, Zeghal K, Rebai T, et al. Evaluation of colistin nephrotoxicity administered at different doses in the rat model. Renal Failure. 2013; 35(8): 1130-5
24.Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2009; 48(12): 1724-8
25.Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. International Journal of Antimicrobial Agents. 2009; 34(5): 434-8
26.Sorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infectious Diseases. 2013; 13: 380
27.Turkoglu M, Dizbay M, Ciftçi A, Aksakal FN, Aygencel G. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction. International Journal of Antimicrobial Agents. 2012; 39(2): 142-5
28.Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrobial Agents and Chemotherapy. 2011; 55(7): 3284-94
29.Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy. 2011; 31(12): 1257-64
30.Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2011; 53(9): 879-84
31.Luo X, Jiang L, Du B, Wen Y, Wang M, Xi X. A comparison of different diagnostic criteria of acute kidney injury in critically ill patients. Critical Care (London, England). 2014; 18(4): R144
32.Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation. 2013; 61(5): 649-72
33.Pereira M, Rodrigues N, Godinho I, Gameiro J, Neves M, Gouveia J, et al. Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the 'Risk, Injury, Failure, Loss of kidney function, End-stage kidney disease' (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) classifications. Clinical Kidney Journal. 2017; 10(3): 332-40
34.Menna P, Salvatorelli E, Mattei A, Cappiello D, Minotti G, Carassiti M. Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy. Chemotherapy. 2018; 63(1): 35-8
35.Honore PM, Jacobs R, Hendrickx I, De Waele E, Van Gorp V, Spapen HD. Higher colistin dose during continuous renal replacement therapy: look before leaping! Critical Care (London, England). 2015; 19(1): 235